Hormonal
Higher habitual levels and increases in plasma phospholipid palmitic acid (16:0), 7-hexadecenoic acid (16:1n-9), and vaccenic acid (18:1n-7) are positively associated with an increased risk of incident heart failure in older adults.
For older adults, maintaining healthy metabolic function is crucial for heart health. While this study doesn't prescribe a specific diet, it highlights that high levels of certain fatty acids (16:0, 16:1n-9, 18:1n-7) in the blood are linked to heart failure risk. These fatty acids are produced by the body (de novo lipogenesis) from excess carbohydrates, sugars, and alcohol, rather than just from eating fat. Therefore, managing carbohydrate and sugar intake may help regulate these fatty acid levels and potentially reduce heart failure risk.
After multivariable adjustment, habitual levels and changes in levels of palmitic acid (16:0) were positively associated with incident HF... Changes in levels of 7-hexadecenoic acid (16:1n-9) and vaccenic acid (18:1n-7) were each positively associated with risk of HF
Why this rating
Large prospective cohort (n=4249), long follow-up (22.1 years), serial biomarker measurements, and multivariable adjustment, but observational design limits causal inference.
Source
Serial Biomarkers of De Novo Lipogenesis Fatty Acids and Incident Heart Failure in Older Adults: The Cardiovascular Health Study
Yujin Lee et al. · Journal of the American Heart Association · 2020
DOI 10.1161/jaha.119.014119
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →